|
Originally published In Press as doi:10.1074/jbc.M207831200 on September 17, 2002
J. Biol. Chem., Vol. 277, Issue 47, 44838-44844, November 22, 2002
Calnexin, Calreticulin, and ERp57 Cooperate in Disulfide Bond
Formation in Human CD1d Heavy Chain*
Suk-Jo
Kang and
Peter
Cresswell
From the Section of Immunobiology, Howard Hughes Medical Institute,
Yale University School of Medicine,
New Haven, Connecticut 06520-8011
Received for publication, August 1, 2002, and in revised form, September 6, 2002
 |
ABSTRACT |
Members of the CD1 family of membrane
glycoproteins can present antigenic lipids to T lymphocytes. Like major
histocompatibility complex class I molecules, they form a
heterodimeric complex of a heavy chain and
2-microglobulin ( 2m) in the
endoplasmic reticulum (ER). Binding of lipid antigens, however, takes
place in endosomal compartments, similar to class II molecules, and on
the plasma membrane. Unlike major histocompatibility complex class I or
CD1b molecules, which need 2m to exit the ER, CD1d can
be expressed on the cell surface as either a free heavy chain or
associated with 2m. These differences led us to
investigate early events of CD1d biosynthesis and maturation and the
role of ER chaperones in its assembly. Here we show that CD1d
associates in the ER with both calnexin and calreticulin and with the
thiol oxidoreductase ERp57 in a manner dependent on glucose trimming of
its N-linked glycans. Complete disulfide bond formation in
the CD1d heavy chain was substantially impaired if the chaperone
interactions were blocked by the glucosidase inhibitors castanospermine
or N-butyldeoxynojirimycin. The formation of at least one
of the disulfide bonds in the CD1d heavy chain is coupled to its
glucose trimming-dependent association with ERp57, calnexin,
and calreticulin.
 |
INTRODUCTION |
CD1 molecules are transmembrane glycoproteins encoded by linked
genes outside the major histocompatibility complex
(MHC)1 (reviewed in Ref. 1).
The human CD1a, -b, and -c molecules constitute group I, whereas human
and mouse CD1d molecules form group II. Like classical MHC class I and
class II molecules, CD1 molecules are recognized by T cells. Certain
 + and  + CD4-CD8 T cells were initially shown to lyse
tumor cells expressing CD1a or CD1c (2). Subsequent studies showed that
mycobacterial lipids, such as mycolic acids, lipoarabinomannan,
phosphatidylinositol mannosides, and hexosyl-1-phosphoisoprenoids could
be presented to cytotoxic T cells by CD1b and CD1c molecules (3-6).
Recently, gangliosides and sulfatides have been identified as natural
host antigens presented by CD1b and CD1a, respectively (7-9). Although no bacterial antigens presented by CD1d molecules have been identified, they present a marine sponge-derived lipid, -galactosylceramide, to
both mouse and human NKT cells (10-15). Recently, natural lipid ligands, including phosphatidylinositol and phosphatidylethanolamine, recognizable by autoreactive CD1d-restricted T cells, have been identified (16).
The structure of CD1 is similar to that of MHC class I molecules in
that CD1 molecules form heterodimers of 43-49-kDa heavy chains
noncovalently associated with 2-microglobulin
( 2m). However, unlike class I molecules, which bind
peptide antigens in the ER, CD1 glycoproteins, like class II molecules,
survey antigens in the endocytic pathway. Peptide binding by class I
molecules is an essential requirement for their egress from the ER.
CD1d molecules may bind autologous lipids in the ER, such as
phosphatidylinositol or glycosylphosphatidylinositol (17, 18), to
satisfy quality control mechanisms and allow transport, before
exchanging them in the endocytic pathway for other autologous or
foreign lipids.
Previous studies have examined the assembly of CD1 molecules. CD1b
heavy chain was observed to bind calnexin and calreticulin in the ER
and to require 2m for subsequent transport to the cell surface (19, 20). In contrast, mouse and human CD1d molecules are
expressed both as free heavy chains and as complexes with 2m. This was observed not only in transfectants but also
in primary tissue cells (21-23). CD1d expressed in
2m-negative cells is fully capable of activating cognate
T cells (23, 24), indicating that heterodimer formation may not be
critical for CD1d function. Although a recent study showed that
2m seems to modulate the structure of the heavy chain
carbohydrates (22), the underlying mechanisms regulating CD1d
expression with or without 2m remain to be elucidated.
Here we present a detailed analysis of CD1d biosynthesis and an
examination of the roles of ER chaperones in CD1d assembly. We show
that CD1d heavy chains associate with calnexin, calreticulin, and the
thiol oxidoreductase ERp57 and demonstrate a role for this association
in the formation of CD1d heavy chain disulfide bonds.
 |
MATERIALS AND METHODS |
Cell Lines--
The B-LCL C1R and .221, and their CD1d
transfectants, were maintained in Iscove's medium
(Invitrogen) containing 5% bovine calf serum or 10% fetal
bovine serum at 37 °C.
Antibodies and Reagents--
The mouse mAbs to human CD1d,
51.1.3 (22, 25, 26) and D5 (22, 26, 27), were gifts from Dr. S. Porcelli (Albert Einstein College of Medicine) and Dr. S. Balk (Harvard
Medical School), respectively. The mAbs GAP.A3 (anti-HLA-A3 (28)),
MaP.ERp57 (anti-ERp57 (29)), and HC10 (anti-class I (30)) have been previously described. The mAb AF8 (anti-calnexin (31)) was a gift from
Dr. M. Brenner (Harvard Medical School). The rabbit anti-calreticulin
serum and rat anti-Grp94 mAb were purchased from StressGen
Biotechnologies Corp. (Victoria, BC, Canada) and anti- 2m
serum from Roche Applied Science (Indianapolis, IN). Dithiobis(succinimidylpropionate) (DSP) was purchased from Pierce and
castanospermine (CST) from Roche Applied Science.
N-Butyldeoxynojirimycin was a gift of Dr. K. Cannon
(32).
Generation of Stable Transfectant Cell Lines--
The vector
CD1d/pSR -neo was a gift of Dr. S. Porcelli. C1R and .221 cells were
transfected by electroporation at 230 and 210 V/960 microfarads,
respectively. C1R.CD1d and .221.CD1d were selected for neomycin
resistance at 1.8 and 0.6 mg/ml G418, respectively. They were screened
for CD1d expression by flow cytometry.
Metabolic Labeling and Immunoprecipitation--
Labeling with
[35S]methionine and cysteine (ICN, Costa Mesa, CA),
immunoprecipitations, and endoglycosidase H (Endo H) digestion were
performed as previously described (33). Reimmunoprecipitation experiments were performed as described (34). For elution in reducing
conditions, washed primary immunoprecipitates were boiled for 5 min in
100 µl of 1% SDS, 5 mM dithiothreitol (DTT), TBS (10 mM Tris, 150 mM NaCl, pH 7.4) before
diluting with 1 ml of 1% Triton X-100, 10 mM
iodoacetamide, TBS. For nonreducing elution, DTT and iodoacetamide were
omitted. The beads were centrifuged and the supernatants were used for
the second immunoprecipitations. The samples were boiled with Laemmli
SDS sample buffer and separated by reducing, unless indicated
otherwise, SDS-PAGE prior to autoradiography. All quantitation was
performed using Bio-Rad GS-525 phosphorimaging and Molecular
Analyst Software.
Cross-linking with DSP--
Cells were metabolically labeled for
45 min and lysed on ice in 1% digitonin in Dulbecco's
phosphate-buffered saline (Invitrogen) with or without 1 mM
DSP. Lysates were diluted in 1% digitonin or 1.2% Triton X-100 before immunoprecipitation.
 |
RESULTS |
Assembly and Transport of CD1d Molecules--
CD1d biosynthesis
was examined in the B-LCL, C1R.CD1d, which is capable of activating
CD1d-specific T cells (15). Cells were labeled with
[35S]methionine/cysteine for 15 min and chased up to
20 h. They were lysed in 1% Triton X-100 and immunoprecipitated
with the anti-CD1d antibodies, 51.1.3 or D5, which recognize heavy
chain- 2m dimers and free heavy chains, respectively.
Exit from the ER was monitored by loss of susceptibility to Endo H. Fig. 1 shows that the majority of Endo
H-sensitive free heavy chains were converted to heavy chain- 2m complexes within 2 h (Fig. 1B).
Both 2m-associated CD1d heavy chains and the residual
free heavy chains underwent complex carbohydrate modification,
manifested as smeared bands, starting at about 1 h for the
heterodimer and 2-4 h for the free heavy chains. Concomitant loss of
Endo H-sensitive bands indicates transport from the ER, and these
results indicate that 2m facilitates, but is not
essential for, CD1d exit from the ER. That 51.1.3-recognizable CD1d is
associated with 2m was confirmed by comparing kinetics of maturation by immunoprecipitation with 51.1.3 and with
anti- 2m serum. The immunoprecipitates were eluted from
the beads by boiling in 1% SDS/DTT/TBS, diluted in 1% Triton
X-100/iodoacetamide/TBS, and the supernatants were reimmunoprecipitated
with D5. Immunoprecipitation with either antibody showed identical CD1d
transport kinetics in C1R.CD1d and in a second CD1d-expressing cell
line, .221.CD1d (Fig. 1C).

View larger version (53K):
[in this window]
[in a new window]
|
Fig. 1.
Kinetics of CD1d maturation.
A, C1R.CD1d cells (2 × 106 cells/lane)
were labeled with [35S]methionine/cysteine for 15 min and
chased up to 20 h. The cells were extracted in 1% Triton X-100
and immunoprecipitated with mAbs 51.1.3 (anti-CD1d/ 2m)
or D5 (anti-CD1d heavy chain). The immunoprecipitates were eluted by
boiling in 0.2% SDS, 0.04 M sodium phosphate buffer, pH
6.5, and the supernatants were incubated with or without Endo H
overnight before analysis by 12% SDS-PAGE. CD1d heavy chain
(R, Endo H resistant; S, Endo H sensitive) and
2m are indicated on the right. B,
quantitation of band intensities using Bio-Rad GS-525 phosphorimaging.
Left panel, CD1d/ 2m and CD1d free heavy chain
as a percentage of maximum. Right panel, Endo H-sensitive
and -resistant CD1d/ 2m and CD1d free heavy chain as a
percentage of total CD1d. C, C1R.CD1d (2 × 106 cells/lane, upper panels) and .221.CD1d
cells (2 × 106 cells/lane, lower panels)
were radiolabeled as in panel A. Cells were extracted in 1%
Triton X-100 and immunoprecipitated with 51.1.3 (left
panels) or rabbit anti- 2m serum (right
panels). CD1d heavy chains were SDS/DTT-eluted,
reimmunoprecipitated with D5, incubated with or without Endo
H, and analyzed by 12% SDS-PAGE.
|
|
To examine how fast CD1d heterodimers arrive at the cell surface,
C1R.CD1d cells were radiolabeled for 15 min and chased up to 8 h.
At each chase point, surface CD1d was captured by incubating the cells
with the 51.1.3 mAb. Unbound 51.1.3 was removed by washing and the
surface CD1d was isolated by adding protein G-Sepharose after lysis.
The residual, mostly intracellular, CD1d was immunoprecipitated by
adding additional 51.1.3 and protein G-Sepharose (Fig.
2A). The immunoprecipitates
were eluted from the beads, and released CD1d heavy chains were
reimmunoprecipitated with the D5 mAb. The results showed that CD1d was
detectable at the cell surface after 1 h and reached a plateau
after ~2.5 h (Fig. 2, B, upper panel, and
C). The rate of transport to the cell surface was
approximately the same as the rate of complex carbohydrate modification
(Figs. 1 and 2B, lower panel). This suggests that
the majority of newly synthesized CD1d is transported along the
secretory pathway through the Golgi to the cell surface without
detouring through endosomal compartments like class II molecules.
Transport to the cell surface is not as rapid as seen for MHC class I
molecules, but is faster than for MHC class II, a pattern very similar
to that observed for CD1b (35). We observed similar surface transport
kinetics by using a surface biotinylation technique (data not
shown).

View larger version (25K):
[in this window]
[in a new window]
|
Fig. 2.
Kinetics of surface arrival of CD1d.
A, experimental scheme of surface binding experiment.
B, C1R.CD1d cells (5 × 106 cells/lane)
were labeled with [35S]methionine/cysteine for 15 min and
chased for the indicated times. Cells were incubated with mAb 51.1.3 (anti-CD1d/ 2m) in 1% bovine serum
albumin/phosphate-buffered saline on ice for 30 min and washed to
remove unbound antibody. After lysing the cells in 1% Triton X-100,
surface CD1d was isolated by incubating with protein G-Sepharose. The
supernatants were cleared with protein G-Sepharose and residual CD1d
was immunoprecipitated with 51.1.3 and protein G-Sepharose. The
immunoprecipitates were SDS/DTT-eluted, CD1d heavy chains were
reimmunoprecipitated with the mAb D5 and analyzed by 12% SDS-PAGE.
C, quantitation of the data in panel B
(A.U., arbitrary units).
|
|
Association of CD1d with ER Chaperones--
To determine whether
the ER-resident proteins involved with the assembly of MHC class I
molecules associate with CD1d, we performed co-immunoprecipitations in
the detergent digitonin, conditions where their interactions with class
I are maintained. Class I heavy chains bound calnexin, calreticulin,
ERp57, the transporter associated with antigen processing (TAP), and
tapasin, whereas CD1d associated only with the chaperones calnexin and calreticulin (data not shown). This is consistent with previous studies
of TAP-deficient cells that showed that the class I peptide loading
complex is not involved with CD1d assembly (36, 37). We also observed
normal surface expression of CD1d in the tapasin-negative .220 B-LCL
(38) transfected with CD1d (data not shown).
Calnexin and calreticulin are homologous lectin domain-containing ER
chaperones that regulate glycoprotein folding in the ER by interacting
with their N-linked glycans (reviewed in Ref. 39). After
transfer to a protein two terminal glucose residues are removed from
the glycan by glucosidase I. Glycoproteins bearing monoglucosylated
N-linked glycans bind calnexin and calreticulin through
their lectin domains and undergo folding and assembly. After release by
the action of glucosidase II, which removes the terminal glucose,
proper folding is monitored by the enzyme UDP-glucose:glycoprotein glucosyltransferase, which reglucosylates the N-linked
glycans of nonnative structures. A correct conformation allows the
glycoprotein to avoid reglucosylation and further interactions with
calnexin and calreticulin. To determine whether calnexin and
calreticulin association with CD1d is dependent on glucose trimming,
radiolabeled C1R.CD1d cells were incubated with the glucosidase
inhibitor CST for various times. Calnexin and calreticulin
dissociation from CD1d was inhibited by CST, indicating that both
interactions are glycan-dependent (data not shown).
Regulation of Disulfide Bond Formation in CD1d--
Calnexin and
calreticulin cooperate with the thiol oxidoreductase ERp57 to
facilitate the formation or isomerization of disulfide bonds during
glycoprotein folding (40-43). To investigate this for CD1d we first
examined the redox state of CD1d heavy chains at various stages; the
forms associated with calnexin or calreticulin, the
2m-free, D5-reactive immature form, and the
2m-associated, 51.1.3-reactive mature form. C1R.CD1d
cells were labeled for 45 min and extracts were immunoprecipitated with
51.1.3, D5, anti-calnexin, or anti-calreticulin antibodies.
Anti-chaperone immunoprecipitates were eluted under nonreducing
conditions (1% SDS and boiling), diluted in Triton X-100, and CD1d
heavy chains were reimmunoprecipitated with D5. After treatment with
Endo H to remove N-linked glycans and improve resolution,
SDS-PAGE analysis showed that, whereas all forms of CD1d had identical
mobilities under reducing conditions, there were differences under
nonreducing conditions, reflecting differences in oxidation states
(Fig. 3). 2m-associated
CD1d heavy chains had the greatest mobility, i.e. were the
most oxidized, whereas the calnexin- and calreticulin-associated forms
and the D5-recognized form showed the same two bands. One is identical in mobility to the putatively fully oxidized, 51.1.3-recognized form,
whereas the second is intermediate between that form and that seen upon
complete reduction, consistent with only one of the internal disulfide
bonds being oxidized.

View larger version (21K):
[in this window]
[in a new window]
|
Fig. 3.
Oxidation states of CD1d associated with
calnexin and calreticulin. C1R.CD1d cells (3 × 106 cells/lane) were labeled with
[35S]methionine/cysteine for 45 min, lysed in 1%
digitonin, and immunoprecipitated with a control mAb GAP.A3 (control,
lanes 5 and 6), anti-calreticulin serum
(lanes 1 and 10), AF8 (anti-calnexin, lanes
2 and 9), 51.1.3 (anti-CD1d/ 2m,
lanes 3 and 7), or D5 (anti-CD1d heavy chain,
lanes 4 and 8). The immunoprecipitates with AF8
and anti-calreticulin antibody were eluted in 1% SDS under nonreducing
conditions, diluted in 1% Triton X-100, and CD1d heavy chains were
reimmunoprecipitated with D5. All the immunoprecipitates were treated
with Endo H overnight and analyzed by 12% SDS-PAGE under nonreducing
(lanes 1-5) and reducing conditions (lanes
6-10). Fully reduced (Red), partially oxidized
(Ox*), and fully oxidized (Ox) CD1d heavy chains
are indicated.
|
|
Glycosylation-dependent Interaction of Free CD1d Heavy
Chains with Calnexin, Calreticulin, and ERp57--
We did not detect
ERp57 association with CD1d under conditions that maintain the
association between ERp57 and the class I loading complex (data not
shown). However, detergents disrupt the interaction of ERp57 with most
glycoproteins. We therefore used a cross-linking agent to preserve the
interaction. C1R.CD1d cells were labeled for 45 min and lysed in 1%
digitonin in the absence or presence of the reducible cross-linking
agent, DSP (1 mM). The extracts were diluted in 1% Triton
X-100 and immunoprecipitated with antibodies to ERp57, calnexin,
calreticulin, and, as a negative control, Grp94. After elution in SDS,
CD1d heavy chains were reimmunoprecipitated with the mAb D5 followed by
reducing SDS-PAGE. The results show that CD1d remains associated with
ERp57 only if cross-linker is added (Fig.
4A). The association of CD1d
with calnexin and calreticulin was maintained in Triton X-100 without
the cross-linker, and no interaction with Grp94 was observed regardless
of the presence of the cross-linker.

View larger version (25K):
[in this window]
[in a new window]
|
Fig. 4.
CD1d heavy chain associates with ERp57 in
concert with calnexin and calreticulin in a glucose
trimming-dependent manner. A, association
of CD1d with ERp57. C1R.CD1d cells (5 × 106
cells/lane) were labeled with [35S]methionine/cysteine
for 45 min and lysed on ice in 1% digitonin with or without the
reducible cross-linker DSP (1 mM). Lysates were diluted in
1.2% Triton X-100 and immunoprecipitated with a control mAb GAP.A3
(lanes 1 and 2), Map.ERp57 (anti-ERp57,
lanes 3 and 4), AF8 (anti-calnexin, lanes
5 and 6), rabbit anti-calreticulin serum (lanes
7 and 8), or rat anti-Grp94 mAb (lanes 9 and
10). Immunoprecipitates were eluted in 1% SDS/TBS and CD1d
heavy chains were reimmunoprecipitated with D5 followed by analysis
using 10% reducing SDS-PAGE. Grp94, an ER-resident protein, was used
as a negative control. B, CD1d heavy chains form a ternary
complex with ERp57 and calnexin or calreticulin. C1R.CD1d cells (5 × 106 cells/lane) were labeled and lysed as in panel
A. Lysates were immunoprecipitated with Map.ERp57. SDS-eluted
immunoprecipitates were reimmunoprecipitated with AF8 (lanes
1 and 2) or anti-calreticulin serum (lanes 3 and 4). The immunoprecipitates were eluted again under
nonreducing conditions, reimmunoprecipitated with D5, and analyzed by
10% reducing SDS-PAGE. C, CD1d association with ERp57 is
glucose trimming-dependent. C1R.CD1d cells (5 × 106 cells/lane) were labeled for 45 min in the absence or
presence of 2 mM CST or 1 mM
N-butyldeoxynojirimycin. Lysates were prepared as in
panel A in the presence of DSP, immunoprecipitated with rat
anti-Grp94 mAb (control; lanes 1, 3, and
5), Map.ERp57 (lanes 2, 4, and
6), AF8 (lanes 7-9), or rabbit anti-calreticulin
serum (lanes 10-12). SDS-eluted materials were
reimmunoprecipitated with D5 and analyzed by 10% SDS-PAGE.
D, upper panels, C1R.CD1d cells (5 × 106 cells/lane) were labeled for 45 min, lysed in 1%
digitonin, and immunoprecipitated with rabbit anti- 2m
serum. Two of the immunoprecipitates were SDS-eluted and
reimmunoprecipitated with HC10 (anti-class I, lane 1) or D5
(lane 4). The rest were competitively eluted with purified
human 2m in 0.1% digitonin and the eluates were
subjected to a second immunoprecipitation with AF8 (lanes 2 and 5) or anti-calreticulin serum (lanes 3 and
6). The materials from the second immunoprecipitation were
SDS-eluted, reimmunoprecipitated with HC10 (lanes 2 and
3) or D5 (lanes 5 and 6), and analyzed
by 12% SDS-PAGE. Class I/ 2m dimers associate with
calreticulin but not calnexin. CD1d/ 2m dimers associate
with neither. Lower panels, cell lysates prepared as in
upper panels were immunoprecipitated with rat anti-Grp94 mAb
(lanes 7 and 10), AF8 (lanes 8 and
11), or anti-calreticulin antibody (lanes 9 and
12). The materials were SDS-eluted, reimmunoprecipitated
with HC10 (lanes 7-9) or D5 (lanes 10-12), and
analyzed in 12% SDS-PAGE. Gels of the D5 immunoprecipitates were
exposed longer to obtain comparable intensities of CD1d and class I
heavy chains. E, CD1d forms a ternary complex with calnexin
and calreticulin. C1R.CD1d cells (5 × 106 cells/lane)
were labeled as in panel A. Digitonin lysates were prepared
in the presence of 1 mM DSP, diluted in 1.2% Triton X-100,
and immunoprecipitated with rat anti-Grp94 mAb (lanes 1 and
3), AF8 (lane 2), or rabbit anti-calreticulin
serum (lane 4). SDS-eluted materials were
reimmunoprecipitated with anti-calreticulin serum (lanes 1 and 2) or AF8 (lanes 3 and 4). The
immunoprecipitates were eluted in nonreducing conditions and CD1d heavy
chains reimmunoprecipitated with D5 followed by analysis using reducing
10% SDS-PAGE.
|
|
By serial immunoprecipitation and SDS stripping, first with anti-ERp57
followed by anti-calnexin or anti-calreticulin and then by anti-CD1d,
we also observed ternary complexes of ERp57, CD1d, and calnexin or
calreticulin when the DSP cross-linker was used (Fig. 4B).
To ask whether ERp57 association with CD1d is glucose
trimming-dependent, C1R.CD1d cells were labeled for 45 min
in the absence or presence of glucosidase inhibitors CST or N-butyldeoxynojirimycin. DSP cross-linked lysates were
immunoprecipitated with antibodies against ERp57, calnexin, or
calreticulin, SDS-eluted, and reimmunoprecipitated with the anti-CD1d
antibody, D5. Analysis by SDS-PAGE showed that ERp57, together with
calnexin and calreticulin, failed to associate with CD1d in the
presence of the inhibitors (Fig. 4C). Previous reports
indicate that ERp57 does not have lectin-like domains (41). These data,
together with other reports (40, 44), indicate that CD1d associates
with ERp57 indirectly via the lectin domains of calnexin or calreticulin.
During assembly of class I molecules newly synthesized free heavy
chains associate with calnexin, whereas class I- 2m
heterodimers associate with calreticulin (45). To determine whether
this is the case for CD1d, C1R.CD1d cells were radiolabeled for 45 min,
lysed in 1% digitonin, and the extract was immunoprecipitated with
anti- 2m serum. 2m-associated
molecules were competitively eluted with human 2m
and reimmunoprecipitated with antibodies against calnexin and
calreticulin. The associated CD1d was detected by
immunoprecipitation with D5. The data show that, whereas class I- 2m dimers (HLA-C molecules in this case) were
co-precipitated with calreticulin, CD1d- 2m dimers were
co-precipitated with neither calnexin nor calreticulin (Fig.
4D). This indicates that both calnexin and calreticulin
interact only with free CD1d heavy chains.
Because both calnexin and calreticulin associate with
2m-free CD1d heavy chain, and CD1d has four
N-glycans,2 it
seemed possible that CD1d heavy chain could form a ternary complex with
both calnexin and calreticulin. This was tested by additional serial
immunoprecipitation/stripping experiments on DSP cross-linked extracts.
The results clearly show the existence of such a ternary complex (Fig.
4E). Given that both calnexin- and calreticulin-associated
CD1d heavy chains are also associated with ERp57, the existence of a
quaternary complex of CD1d, calnexin, calreticulin, and ERp57 seems likely.
The data suggest that disulfide bond formation in CD1d
heavy chains is regulated by ERp57. Given that D5-reactive,
calnexin-associated, and calreticulin-associated CD1d heavy chains show
the same two bands on SDS-PAGE under nonreducing conditions (Fig. 3),
we hypothesized that the D5-reactive partially oxidized form initially
associates with calnexin, calreticulin, and ERp57 and that formation of
the second disulfide bond occurs during association. If this is
correct, inhibition of the CD1d-chaperone interaction should result in the accumulation of D5-reactive partially oxidized CD1d heavy chains.
To test this, C1R.CD1d cells were radiolabeled for 5 min and chased in
the absence or presence of CST. CD1d heavy chains were
immunoprecipitated with D5, treated with Endo H, and subjected to
nonreducing SDS-PAGE. The ratio of partially oxidized to fully oxidized
heavy chains was indeed higher throughout the chase period in the
presence of CST (Fig. 5, A
and B).

View larger version (16K):
[in this window]
[in a new window]
|
Fig. 5.
Glucose trimming-dependent quality control
determines the oxidation state of CD1d. A, C1R.CD1d
cells (1.5 × 106 cells/lane) were labeled for 5 min
and chased in the absence or presence of 2 mM CST. CST was
present during starvation, labeling, and chase periods. Cells were
lysed in 1% Triton X-100, immunoprecipitated with D5 (anti-CD1d heavy
chain), treated with Endo H, and analyzed by nonreducing (upper
panel) or reducing (lower panel) 12% SDS-PAGE. As a
control, extracts of cells (0.75 × 106 cells/lane)
continuously labeled for 45 min, without (lanes 1 and
2) or with (lanes 3 and 4) 2 mM CST, were also immunoprecipitated with D5 (lanes
1 and 3) or 51.1.3 (anti-CD1d/ 2m,
lanes 2 and 4). Partially oxidized
(Ox*) and fully oxidized (Ox) CD1d heavy chains
are indicated. B, quantitation of the results in panel
A presented as the ratio of partially oxidized and oxidized forms
of CD1d heavy chain in the presence and absence of CST.
|
|
 |
DISCUSSION |
A model of the early biogenesis of CD1d molecules based on the
data presented here is depicted in Fig.
6. For simplicity only two of the
N-linked glycans are shown. Calnexin and calreticulin simultaneously associate via monoglucosylated N-linked
glycans with newly synthesized CD1d heavy chains in which one disulfide bond is already formed. Here we show the nonoxidized one as that in the
2 domain although there is no evidence to support this. Calnexin and/or calreticulin bring ERp57 to the 2m-free
CD1d heavy chain and this mediates the formation of the second
disulfide bond. The terminal glucose residues of the
N-linked glycans are trimmed and the fully oxidized CD1d
heavy chain then dissociates from the chaperones. The majority of the
CD1d binds 2m but it can leave the ER even without
it.
Useful comparisons can be made between the assembly pathway illustrated
in Fig. 6 and that of classical MHC class I molecules and even class II
molecules. Both of these pathways involve calnexin, and class I
assembly also involves calreticulin and ERp57. Class II molecules
consist of heterodimers of transmembrane glycoproteins that associate
with trimers of a third glycoprotein, the invariant chain, in the ER.
Intermediates containing one or two  dimers bound to an invariant
chain trimer remain associated with calnexin until the ultimate
nonameric complex with three  dimers is complete (46). Whether
ERp57 plays a role in this process is unknown. In class I assembly,
newly synthesized heavy chains first bind calnexin. Calreticulin
replaces calnexin when 2m binds to the heavy chain, and,
together with associated ERp57, this assembly is recruited to become
part of a multisubunit "peptide loading complex" that also contains
the heterodimeric TAP transporter and transmembrane glycoprotein
tapasin (reviewed in Ref. 47). Recruitment of class I molecules to the
loading complex requires calreticulin (48) and depends upon the
generation of a monoglucosylated N-linked glycan in the
class I heavy chain (40).3
Recently it has been shown that tapasin binds to ERp57 via an interchain disulfide bond, and cooperates with ERp57 in forming the
correct disulfide bonds in the class I heavy chain (49). Formation of
the loading complex, including calreticulin association (48) and
tapasin-mediated ERp57 association, is required for proper peptide
binding to class I molecules, and peptide binding is required for the
class I- 2m dimer to leave the ER (50, 51). Thus, this
whole process can be understood as a unique quality control mechanism
in which all the components, i.e. 2m,
calnexin, calreticulin, ERp57, TAP, tapasin, and even peptides, participate.
There are obviously significant differences between the CD1d and MHC
class I assembly and transport pathways. First, 2m
association is not as critical for CD1d folding as it is for
conventional class I molecules. Complete disulfide bond formation is
achieved before 2m associates with CD1d and
2m-free CD1d heavy chain can leave the ER. This is
further supported by previous studies, which showed that, even in
vivo, 2m is not critical for the function of CD1d.
2m-free CD1d expressed in splenic cells from
2m-deficient mice is fully capable of activating cognate
T cells (23, 24). Second, the point in the assembly process where
calreticulin interacts with MHC class I is different from that with
CD1d. Class I associates with calreticulin only when complexed with
2m, whereas CD1d associates with calreticulin as a free
heavy chain. Moreover, CD1d can form a quaternary complex with
calnexin, calreticulin, and ERp57. Calnexin and calreticulin may bind
to different glycans of the CD1d heavy chain, similar to the situation
with influenza virus hemagglutinin (52). How calnexin and calreticulin
mediate the folding of CD1d heavy chain and which one is responsible
for recruiting ERp57 remains to be elucidated. Surface expression of
CD1d in the calnexin-negative cell CEM.NKR is not
impaired4 so calreticulin may
be more critical for CD1d folding and assembly. Third, class I assembly
may need to be tightly coupled to peptide loading because class I must
survey the available peptides in the ER and optimize the associated
repertoire. Quality control of CD1d may not need to be tightly coupled
to optimal lipid binding in the ER, although lipids may bind there (see
below), because it samples antigenic lipids in the endocytic pathway.
In other words, optimization of antigen binding may be separable from
quality control, being restricted to the place where antigen presenting molecules survey antigens. This is further substantiated by studies of
class Ib molecules, H2-M3, HLA-E, and Qa-1. These are structurally similar to class I molecules but bind hydrophobic peptides,
N-formylated peptides, or signal peptides of class Ia
molecules, respectively. When their cognate peptides are not available,
they are retained in the ER (53-58). Similarly, the stability of class
II molecules is determined by peptide exchange mediated in the
endocytic pathway by DM molecules.
Given the hydrophobic nature of the CD1d binding groove it seems
unlikely that the CD1d molecule would satisfy ER quality control
mechanisms, and avoid reglucosylation of one or more of its
N-linked glycans by UDP-glucose:glycoprotein
glucosyltransferase, unless the groove is occupied. As already
discussed, the binding site of class I molecules must be occupied by
peptides, and the peptide binding site of MHC class II molecules also
must be occupied for efficient transport from the ER, in this case by
the CLIP region of the invariant chain. For the CD1d family, ER-derived lipids, such as the phosphatidylinositol and
glycosylphosphatidylinositol associated with soluble, secreted mouse
CD1d, are the likely occupants of the binding groove in the ER (17,
18).
 |
ACKNOWLEDGEMENT |
We thank Nancy Dometios for help with
preparation of this manuscript.
 |
FOOTNOTES |
*
This work was supported by the Howard Hughes Medical
Institute and National Institutes of Health Grant AI23081.The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in
accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
To whom correspondence should be addressed. Tel.: 203-785-5176;
Fax: 203-737-1764; E-mail: peter.cresswell@yale.edu.
Published, JBC Papers in Press, September 17, 2002, DOI 10.1074/jbc.M207831200
2
S.-J. Kang and P. Cresswell, unpublished observation.
3
Radcliffe, C. M., Diedrich, G., Harvey, D. J.,
Dwek, R. A., Cresswell, P., and Rudd, P. M. (2002) J. Biol. Chem.
277, 46415-46423.
4
S.-J. Kang and P. Cresswell, unpublished data.
 |
ABBREVIATIONS |
The abbreviations used are:
MHC, major
histocompatibility complex;
2m, 2-microglobulin;
B-LCL, B-lymphoblastoid line;
ER, endoplasmic reticulum;
DTT, dithiothreitol;
DSP, dithiobis(succinimidylpropionate);
CST, castanospermine;
mAb, monoclonal antibody;
Endo H, endoglycosidase H;
TAP, transporter-associated with antigen processing;
TBS, Tris-buffered
saline.
 |
REFERENCES |
| 1.
|
Porcelli, S. A.,
and Modlin, R. L.
(1999)
Annu. Rev. Immunol.
17,
297-329[CrossRef][Medline]
[Order article via Infotrieve]
|
| 2.
|
Porcelli, S.,
Brenner, M. B.,
Greenstein, J. L.,
Balk, S. P.,
Terhorst, C.,
and Bleicher, P. A.
(1989)
Nature
341,
447-450[CrossRef][Medline]
[Order article via Infotrieve]
|
| 3.
|
Porcelli, S.,
Morita, C. T.,
and Brenner, M. B.
(1992)
Nature
360,
593-597[CrossRef][Medline]
[Order article via Infotrieve]
|
| 4.
|
Beckman, E. M.,
Porcelli, S. A.,
Morita, C. T.,
Behar, S. M.,
Furlong, S. T.,
and Brenner, M. B.
(1994)
Nature
372,
691-694[CrossRef][Medline]
[Order article via Infotrieve]
|
| 5.
|
Sieling, P. A.,
Chatterjee, D.,
Porcelli, S. A.,
Prigozy, T. I.,
Mazzaccaro, R. J.,
Soriano, T.,
Bloom, B. R.,
Brenner, M. B.,
Kronenberg, M.,
Brennan, P. J.,
and Modlin, R. L.
(1995)
Science
269,
227-230[Abstract/Free Full Text]
|
| 6.
|
Moody, D. B.,
Ulrichs, T.,
Muhlecker, W.,
Young, D. C.,
Gurcha, S. S.,
Grant, E.,
Rosat, J. P.,
Brenner, M. B.,
Costello, C. E.,
Besra, G. S.,
and Porcelli, S. A.
(2000)
Nature
404,
884-888[CrossRef][Medline]
[Order article via Infotrieve]
|
| 7.
|
Shamshiev, A.,
Donda, A.,
Carena, I.,
Mori, L.,
Kappos, L.,
and De Libero, G.
(1999)
Eur. J. Immunol.
29,
1667-1675[CrossRef][Medline]
[Order article via Infotrieve]
|
| 8.
|
Shamshiev, A.,
Donda, A.,
Prigozy, T. I.,
Mori, L.,
Chigorno, V.,
Benedict, C. A.,
Kappos, L.,
Sonnino, S.,
Kronenberg, M.,
and De Libero, G.
(2000)
Immunity
13,
255-264[CrossRef][Medline]
[Order article via Infotrieve]
|
| 9.
|
Shamshiev, A.,
Gober, H. J.,
Donda, A.,
Mazorra, Z.,
Mori, L.,
and De Libero, G.
(2002)
J. Exp. Med.
195,
1013-1021[Abstract/Free Full Text]
|
| 10.
|
Kawano, T.,
Cui, J.,
Koezuka, Y.,
Toura, I.,
Kaneko, Y.,
Motoki, K.,
Ueno, H.,
Nakagawa, R.,
Sato, H.,
Kondo, E.,
Koseki, H.,
and Taniguchi, M.
(1997)
Science
278,
1626-1629[Abstract/Free Full Text]
|
| 11.
|
Brossay, L.,
Naidenko, O.,
Burdin, N.,
Matsuda, J.,
Sakai, T.,
and Kronenberg, M.
(1998)
J. Immunol.
161,
5124-5128[Abstract/Free Full Text]
|
| 12.
|
Brossay, L.,
Chioda, M.,
Burdin, N.,
Koezuka, Y.,
Casorati, G.,
Dellabona, P.,
and Kronenberg, M.
(1998)
J. Exp. Med.
188,
1521-1528[Abstract/Free Full Text]
|
| 13.
|
Brossay, L.,
Tangri, S.,
Bix, M.,
Cardell, S.,
Locksley, R.,
and Kronenberg, M.
(1998)
J. Immunol.
160,
3681-3688[Abstract/Free Full Text]
|
| 14.
|
Burdin, N.,
Brossay, L.,
Koezuka, Y.,
Smiley, S. T.,
Grusby, M. J.,
Gui, M.,
Taniguchi, M.,
Hayakawa, K.,
and Kronenberg, M.
(1998)
J. Immunol.
161,
3271-3281[Abstract/Free Full Text]
|
| 15.
|
Spada, F. M.,
Koezuka, Y.,
and Porcelli, S. A.
(1998)
J. Exp. Med.
188,
1529-1534[Abstract/Free Full Text]
|
| 16.
|
Gumperz, J. E.,
Roy, C.,
Makowska, A.,
Lum, D.,
Sugita, M.,
Podrebarac, T.,
Koezuka, Y.,
Porcelli, S. A.,
Cardell, S.,
Brenner, M. B.,
and Behar, S. M.
(2000)
Immunity
12,
211-221[CrossRef][Medline]
[Order article via Infotrieve]
|
| 17.
|
Joyce, S.,
Woods, A. S.,
Yewdell, J. W.,
Bennink, J. R., De,
Silva, A. D.,
Boesteanu, A.,
Balk, S. P.,
Cotter, R. J.,
and Brutkiewicz, R. R.
(1998)
Science
279,
1541-1544[Abstract/Free Full Text]
|
| 18.
|
De Silva, A. D.,
Park, J. J.,
Matsuki, N.,
Stanic, A. K.,
Brutkiewicz, R. R.,
Medof, M. E.,
and Joyce, S.
(2002)
J. Immunol.
168,
723-733[Abstract/Free Full Text]
|
| 19.
|
Huttinger, R.,
Staffler, G.,
Majdic, O.,
and Stockinger, H.
(1999)
Int. Immunol.
11,
1615-1623[Abstract/Free Full Text]
|
| 20.
|
Sugita, M.,
Porcelli, S. A.,
and Brenner, M. B.
(1997)
J. Immunol.
159,
2358-2365[Abstract/Free Full Text]
|
| 21.
|
Balk, S. P.,
Burke, S.,
Polischuk, J. E.,
Frantz, M. E.,
Yang, L.,
Porcelli, S.,
Colgan, S. P.,
and Blumberg, R. S.
(1994)
Science
265,
259-262[Abstract/Free Full Text]
|
| 22.
|
Kim, H. S.,
Garcia, J.,
Exley, M.,
Johnson, K. W.,
Balk, S. P.,
and Blumberg, R. S.
(1999)
J. Biol. Chem.
274,
9289-9295[Abstract/Free Full Text]
|
| 23.
|
Amano, M.,
Baumgarth, N.,
Dick, M. D.,
Brossay, L.,
Kronenberg, M.,
Herzenberg, L. A.,
and Strober, S.
(1998)
J. Immunol.
161,
1710-1717[Abstract/Free Full Text]
|
| 24.
|
Cardell, S.,
Tangri, S.,
Chan, S.,
Kronenberg, M.,
Benoist, C.,
and Mathis, D.
(1995)
J. Exp. Med.
182,
993-1004[Abstract/Free Full Text]
|
| 25.
|
Exley, M.,
Garcia, J.,
Balk, S. P.,
and Porcelli, S.
(1997)
J. Exp. Med.
186,
109-120[Abstract/Free Full Text]
|
| 26.
|
Exley, M.,
Garcia, J.,
Wilson, S. B.,
Spada, F.,
Gerdes, D.,
Tahir, S. M.,
Patton, K. T.,
Blumberg, R. S.,
Porcelli, S.,
Chott, A.,
and Balk, S. P.
(2000)
Immunology
100,
37-47[CrossRef][Medline]
[Order article via Infotrieve]
|
| 27.
|
Rodionov, D. G.,
Nordeng, T. W.,
Pedersen, K.,
Balk, S. P.,
and Bakke, O.
(1999)
J. Immunol.
162,
1488-1495[Abstract/Free Full Text]
|
| 28.
|
Berger, A. E.,
Davis, J. E.,
and Cresswell, P.
(1982)
Hybridoma
1,
87-90[Medline]
[Order article via Infotrieve]
|
| 29.
|
Diedrich, G.,
Bangia, N.,
Pan, M.,
and Cresswell, P.
(2001)
J. Immunol.
166,
1703-1709[Abstract/Free Full Text]
|
| 30.
|
Stam, N. J.,
Spits, H.,
and Ploegh, H. L.
(1986)
J. Immunol.
137,
2299-2306[Abstract]
|
| 31.
|
Hochstenbach, F.,
David, V.,
Watkins, S.,
and Brenner, M. B.
(1992)
Proc. Natl. Acad. Sci. U. S. A.
89,
4734-4738[Abstract/Free Full Text]
|
| 32.
|
Cannon, K. S.,
and Cresswell, P.
(2001)
EMBO J.
20,
2443-2453[CrossRef][Medline]
[Order article via Infotrieve]
|
| 33.
|
Denzin, L. K.,
Hammond, C.,
and Cresswell, P.
(1996)
J. Exp. Med.
184,
2153-2165[Abstract/Free Full Text]
|
| 34.
|
Kang, S. J.,
and Cresswell, P.
(2002)
EMBO J.
21,
1650-1660[CrossRef][Medline]
[Order article via Infotrieve]
|
| 35.
|
Briken, V.,
Jackman, R. M.,
Dasgupta, S.,
Hoening, S.,
and Porcelli, S. A.
(2002)
EMBO J.
21,
825-834[CrossRef][Medline]
[Order article via Infotrieve]
|
| 36.
|
Brutkiewicz, R. R.,
Bennink, J. R.,
Yewdell, J. W.,
and Bendelac, A.
(1995)
J. Exp. Med.
182,
1913-1919[Abstract/Free Full Text]
|
| 37.
|
Teitell, M.,
Holcombe, H. R.,
Brossay, L.,
Hagenbaugh, A.,
Jackson, M. J.,
Pond, L.,
Balk, S. P.,
Terhorst, C.,
Peterson, P. A.,
and Kronenberg, M.
(1997)
J. Immunol.
158,
2143-2149[Abstract]
|
| 38.
|
Ortmann, B.,
Copeman, J.,
Lehner, P. J.,
Sadasivan, B.,
Herberg, J. A.,
Grandea, A. G.,
Riddell, S. R.,
Tampe, R.,
Spies, T.,
Trowsdale, J.,
and Cresswell, P.
(1997)
Science
277,
1306-1309[Abstract/Free Full Text]
|
| 39.
|
Ellgaard, L.,
and Helenius, A.
(2001)
Curr. Opin. Cell Biol.
13,
431-437[CrossRef][Medline]
[Order article via Infotrieve]
|
| 40.
|
Elliott, J. G.,
Oliver, J. D.,
and High, S.
(1997)
J. Biol. Chem.
272,
13849-13855[Abstract/Free Full Text]
|
| 41.
|
Zapun, A.,
Darby, N. J.,
Tessier, D. C.,
Michalak, M.,
Bergeron, J. J.,
and Thomas, D. Y.
(1998)
J. Biol. Chem.
273,
6009-6912[Abstract/Free Full Text]
|
| 42.
|
Oliver, J. D.,
Roderick, H. L.,
Llewellyn, D. H.,
and High, S.
(1999)
Mol. Biol. Cell
10,
2573-2582[Abstract/Free Full Text]
|
| 43.
|
Molinari, M.,
and Helenius, A.
(1999)
Nature
402,
90-93[CrossRef][Medline]
[Order article via Infotrieve]
|
| 44.
|
Van der Wal, F. J.,
Oliver, J. D.,
and High, S.
(1998)
Eur. J. Biochem.
256,
51-59[Medline]
[Order article via Infotrieve]
|
| 45.
|
Sadasivan, B.,
Lehner, P. J.,
Ortmann, B.,
Spies, T.,
and Cresswell, P.
(1996)
Immunity
5,
103-114[CrossRef][Medline]
[Order article via Infotrieve]
|
| 46.
|
Anderson, K. S.,
and Cresswell, P.
(1994)
EMBO J.
13,
675-682[Medline]
[Order article via Infotrieve]
|
| 47.
|
Cresswell, P.,
Bangia, N.,
Dick, T.,
and Diedrich, G.
(1999)
Immunol. Rev.
172,
21-28[CrossRef][Medline]
[Order article via Infotrieve]
|
| 48.
|
Gao, B.,
Adhikari, R.,
Howarth, M.,
Nakamura, K.,
Gold, M. C.,
Hill, A. B.,
Knee, R.,
Michalak, M.,
and Elliott, T.
(2002)
Immunity
16,
99-109[CrossRef][Medline]
[Order article via Infotrieve]
|
| 49.
|
Dick, T. P.,
Bangia, N.,
Peaper, D. R.,
and Cresswell, P.
(2002)
Immunity
16,
87-98[CrossRef][Medline]
[Order article via Infotrieve]
|
| 50.
|
Degen, E.,
Cohen-Doyle, M. F.,
and Williams, D. B.
(1992)
J. Exp. Med.
175,
1653-1661[Abstract/Free Full Text]
|
| 51.
|
Sugita, M.,
and Brenner, M. B.
(1994)
J. Exp. Med.
180,
2163-2171[Abstract/Free Full Text]
|
| 52.
|
Hebert, D. N.,
Zhang, J. X.,
Chen, W.,
Foellmer, B.,
and Helenius, A.
(1997)
J. Cell Biol.
139,
613-623[Abstract/Free Full Text]
|
| 53.
|
Chiu, N. M.,
Chun, T.,
Fay, M.,
Mandal, M.,
and Wang, C. R.
(1999)
J. Exp. Med.
190,
423-434[Abstract/Free Full Text]
|
| 54.
|
Chun, T.,
Grandea, A. G., 3rd,
Lybarger, L.,
Forman, J.,
Van Kaer, L.,
and Wang, C. R.
(2001)
J. Immunol.
167,
1507-1514[Abstract/Free Full Text]
|
| 55.
|
Lybarger, L., Yu, Y. Y.,
Chun, T.,
Wang, C. R.,
Grandea, A. G., 3rd,
Van Kaer, L.,
and Hansen, T. H.
(2001)
J. Immunol.
167,
2097-2105[Abstract/Free Full Text]
|
| 56.
|
Lee, N.,
Goodlett, D. R.,
Ishitani, A.,
Marquardt, H.,
and Geraghty, D. E.
(1998)
J. Immunol.
160,
4951-4960[Abstract/Free Full Text]
|
| 57.
|
Bai, A.,
Broen, J.,
and Forman, J.
(1998)
Immunity
9,
413-421[CrossRef][Medline]
[Order article via Infotrieve]
|
| 58.
|
Bai, A.,
Aldrich, C. J.,
and Forman, J.
(2000)
J. Immunol.
165,
7025-7034[Abstract/Free Full Text]
|
Copyright © 2002 by The American Society for Biochemistry and Molecular Biology, Inc.

CiteULike Complore Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
C. Gelin, I. Sloma, D. Charron, and N. Mooney
Regulation of MHC II and CD1 antigen presentation: from ubiquity to security
J. Leukoc. Biol.,
February 1, 2009;
85(2):
215 - 224.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. Grillo, C. D'Ambrosio, V. Consalvi, R. Chiaraluce, A. Scaloni, M. Maceroni, M. Eufemi, and F. Altieri
DNA-binding Activity of the ERp57 C-terminal Domain Is Related to a Redox-dependent Conformational Change
J. Biol. Chem.,
April 6, 2007;
282(14):
10299 - 10310.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. K. Dougan, P. Rava, M. M. Hussain, and R. S. Blumberg
MTP regulated by an alternate promoter is essential for NKT cell development
J. Exp. Med.,
March 19, 2007;
204(3):
533 - 545.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. Kawana, A. J. Quayle, M. Ficarra, J. A. Ibana, L. Shen, Y. Kawana, H. Yang, L. Marrero, S. Yavagal, S. J. Greene, et al.
CD1d Degradation in Chlamydia trachomatis-infected Epithelial Cells Is the Result of Both Cellular and Chlamydial Proteasomal Activity
J. Biol. Chem.,
March 9, 2007;
282(10):
7368 - 7375.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. Paduraru, L. Spiridon, W. Yuan, G. Bricard, X. Valencia, S. A. Porcelli, P. A. Illarionov, G. S. Besra, S. M. Petrescu, A.-J. Petrescu, et al.
An N-Linked Glycan Modulates the Interaction between the CD1d Heavy Chain and beta2-Microglobulin
J. Biol. Chem.,
December 29, 2006;
281(52):
40369 - 40378.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. K. Dougan, A. Salas, P. Rava, A. Agyemang, A. Kaser, J. Morrison, A. Khurana, M. Kronenberg, C. Johnson, M. Exley, et al.
Microsomal triglyceride transfer protein lipidation and control of CD1d on antigen-presenting cells
J. Exp. Med.,
August 15, 2005;
202(4):
529 - 539.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
X. Zhu, J. Peng, D. Chen, X. Liu, L. Ye, H. Iijima, K. Kadavil, W. I. Lencer, and R. S. Blumberg
Calnexin and ERp57 Facilitate the Assembly of the Neonatal Fc Receptor for IgG with {beta}2-Microglobulin in the Endoplasmic Reticulum
J. Immunol.,
July 15, 2005;
175(2):
967 - 976.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. G. Santos, S. J. Powis, and F. A. Arosa
Misfolding of Major Histocompatibility Complex Class I Molecules in Activated T Cells Allows cis-Interactions with Receptors and Signaling Molecules and Is Associated with Tyrosine Phosphorylation
J. Biol. Chem.,
December 17, 2004;
279(51):
53062 - 53070.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
O. Ben-Zeev and M. H. Doolittle
Maturation of Hepatic Lipase: FORMATION OF FUNCTIONAL ENZYME IN THE ENDOPLASMIC RETICULUM IS THE RATE-LIMITING STEP IN ITS SECRETION
J. Biol. Chem.,
February 13, 2004;
279(7):
6171 - 6181.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J.-J. Park, S.-J. Kang, A. D. De Silva, A. K. Stanic, G. Casorati, D. L. Hachey, P. Cresswell, and S. Joyce
Lipid-protein interactions: Biosynthetic assembly of CD1 with lipids in the endoplasmic reticulum is evolutionarily conserved
PNAS,
January 27, 2004;
101(4):
1022 - 1026.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
G. Negroiu, R. A. Dwek, and S. M. Petrescu
The Inhibition of Early N-Glycan Processing Targets TRP-2 to Degradation in B16 Melanoma Cells
J. Biol. Chem.,
July 11, 2003;
278(29):
27035 - 27042.
[Abstract]
[Full Text]
[PDF]
|
 |
|
Copyright © 2002 by the American Society for Biochemistry and Molecular Biology.
|
Advertisement
Advertisement
|